The problem of multiple diseases and disability caused by aging is the core reason for the profound impact of population aging on the whole field of economic operation, all links of social construction, social and cultural aspects, as well as the comprehensive strength and international competitiveness of the country. Based on the "prevention of disease" thought of traditional Chinese medicine, it is necessary to strengthen the concept of prevention to actively respond to the aging of the population, promote healthy aging, and actively prevent the emergence of the problem of disability of the aging population due to multiple diseases. We will organically combine prevention before aging, prevention of aging, prevention of disease after aging, prevention of dementia and disability after aging, and take active anti-aging measures to delay or even prevent the decline of physical functions of the elderly population, so as to achieve the goal of healthy aging of the elderly population without getting sick, less sick, late sick, no serious disease, and can recover quickly after getting sick, and fundamentally reduce the medical, health care, elderly care Social and economic pressures such as home care.

Objective To analyze the relationship between peripheral blood fulin(Furin), soluble tumor necrosis factor like weak apoptotic inducer(sTWEAK), neutrophil/lymphocyte ratio(NLR), myocardial injury indicators, and poor prognosis in patients with type H hypertension(HHT) and acute myocardial infarction(AMI). Methods Two hundred and thirty-one patients with HHT and AMI treated in the Cardiovascular Department of Fangshan Hospital, Beijing University of Chinese Medicine from January 2019 to February 2021 were selected as the HHT+AMI group, 77 patients with HHT only were selected as the HHT group, and 52 healthy examinees from the hospital were selected as the healthy control group. The peripheral blood levels of Furin, sTWEAK, NLR, and serum myocardial injury indicators [creatine kinase isoenzyme(CK-MB), cardiac troponin I(cTnI), N-terminal pro-brain natriuretic peptide(NT-proBNP)] were compared among the three groups, and the correlation between peripheral blood levels of Furin, sTWEAK, NLR, and myocardial injury indicators was analyzed. The main adverse cardiovascular events(MACE) in the HHT+AMI group were recorded during a 1-year follow-up, and logistic regression was used to analyze the factors influencing the occurrence of MACE in HHT+AMI patients. The receiver operating characteristic(ROC) curve was plotted to analyze the predictive value of the three factors for MACE in HHT+AMI patients. Results Comparison of peripheral blood Furin, sTWEAK, and NLR levels in HHT+AMI group>HHT group>healthy control group(F/P=981.029/<0.001, 1 032.486/<0.001, 326.617/<0.001), and MACE subgroup was higher than non MACE subgroup(t/P=19.498/<0.001, 17.909/<0.001, 2.507/<0.001); The levels of CK-MB in HHT+AMI group were higher than those in HHT group and healthy control group, and the levels of serum cTnI and NT-proBNP in HHT+AMI group were higher than those in HHT group and healthy control group(F/P=580.966/<0.001, 672.830/<0.001, 463.233/<0.001); Peripheral blood Furin, sTWEAK, and NLR were significantly positively correlated with serum CK-MB, cTnI, and NT-proBNP(Furin: r/P=0.713/<0.001, 0.604/<0.001, 0.515/<0.001; sTWEAK:r/P=0.412/0.002, 0.533/<0.001, 0.502/<0.001; NLR:r/P=0.513/<0.001, 0.554/<0.001, 0.481/<0.001); Killip III/IV, high Gensini score, high Furin, high sTWEAK, and high NLR are independent risk factors for MACE in patients with HHT and AMI [OR(95%CI)=1.725(1.178 to 2.524), 1.571(1.160 to 2.128), 2.412(1.527 to 3.806), 2.204(1.421 to 3.418), 1.784(1.213 to 2.624)]. The area under the curve(AUC) of peripheral blood Furin, sTWEAK, NLR, and their combined detection in predicting MACE in patients with HHT and AMI were 0.740, 0.715, 0.693, and 0.841, respectively. The combined prediction efficacy of the three indicators was better than that of each indicator alone(Z/P=2.038/0.042, 2.459/0.014, 4.037/<0.001). Conclusion Furin, sTWEAK, and NLR are abnormally elevated in the peripheral blood of patients with HHT and AMI, and are closely related to myocardial injury and poor prognosis. The combined detection of the three can be used as a reference basis for predicting poor prognosis in patients with HHT and AMI.

Objective To observe the clinical effect of Qiliqiangxin Capsule combined with levosimendan injection in the treatment of elderly patients with acute myocardial infarction(AMI) and left heart failure(HF). Methods From February 2019 to September 2021, 82 patients with AMI and HF diagnosed and treated by the Second Department of Cardiovascular Disease, Affiliated Hospital of Shandong University of Traditional Chinese Medicine were randomly divided into a control group and an observation group, with 41 patients in each group. The control group was treated with levosimendan injection, and the observation group was treated with Qiliqiangxin Capsule on the basis of the control group. Observe the clinical efficacy of the two groups, the score of traditional Chinese medicine syndromes before and after treatment, cardiac color ultrasound indicators(left ventricular ejection fraction(LVEF), E/A value, left ventricular Tei index), laboratory examination indicators(partial pressure of carbon dioxide(PaCO2), partial pressure of oxygen(PaO2), N-terminal proBNP precursor(NT-proBNP), troponin I(cTNI), high sensitivity C-reactive protein(hs-CRP), and homocysteine level(Hcy)), The incidence of major adverse cardiovascular events(MACE) was recorded during a one-year follow-up. Results After treatment, the total effective rate of the observation group was higher than that of the control group(90.24% vs. 78.05%,χ2/P=6.104/0.047); the TCM syndrome scores of both groups(aversion to cold and cold limbs, limb edema, palpitations and shortness of breath, coldness in the waist and abdomen, difficulty urinating) were lower than before treatment, and the scores of the observation group were lower than those of the control group(t/P=2.796/0.006, 2.357/0.021, 2.015/0.047, 2.632/0.010, 2.507/0.014); LVEF and E/A values of both groups increased and left ventricular Tei index decreased after treatment, and the increase/decrease amplitude of the observation group was greater than that of the control group(t/P=3.156/0.002, 3.211/0.002, 3.604/0.001); cTNI, Hcy, NT-proBNP, hs-CRP, and PaCO2 levels of both groups decreased, and PaO2 increased after treatment. The levels of Hcy, NT-proBNP, hs-CRP, and PaCO2 in the observation group were lower than those in the control group, and the PaO2 level was higher than that in the control group(t/P=2.651/0.010, 2.872/0.005, 7.560/<0.001, 7.851/<0.001, 6.632/<0.001). there="" was="" no="" significant="" difference="" in="" ctni="" levels="" between="" the="" two="" p="">0.05); the incidence of all-cause mortality, acute fatal myocardial infarction, and acute heart failure in the observation group was lower than that in the control group(χ2/P=4.440/0.035, 3.888/0.049, 4.497/0.034).. Conclusion The clinical efficacy of Qiliqiangxin Capsule combined with levosimendan injection in the treatment of elderly patients with acute myocardial infarction and left heart failure is significant.

Objective To analyze the activity of renin angiotensin system and its correlation with atrial fibrillation(AF) in patients with coronary heart disease and hyperthyroidism. Methods From April 2020 to July 2022, 75 patients with coronary heart disease admitted to the Shanxi Provincial Cardiovascular Hospital were selected as the coronary heart disease group, 75 patients with coronary heart disease combined with hyperthyroidism as the hyperthyroidism group, and 75 healthy subjects in the same period were selected as the healthy control group. The renin angiotensin system activity [plasma renin(PRA), angiotensin converting enzyme(ACE), angiotensin II(AT II), and left atrial diameter(LAD)] of the subjects in each group were compared, Pearson was used to analyze the correlation between the activity of the renin angiotensin system and thyroid stimulating hormone(TSH), serum free triiodothyronine(FT3), serum free thyroxine(FT4), and LAD. Multivariate logistic regression was used to analyze the related influencing factors of atrial fibrillation in patients with coronary heart disease and hyperthyroidism. Results The levels of PRA, ACE, AT Ⅱ, and LAD in patients with hyperthyroidism were higher than those in patients with coronary heart disease and healthy controls(P<0.05); The levels of PRA, ACE, AT Ⅱ, and LAD in patients with atrial fibrillation in the coronary heart disease group and hyperthyroidism group were higher than those without atrial fibrillation(P<0.05). The levels of patients with atrial fibrillation in the hyperthyroidism group were higher than those in the coronary heart disease group(P<0.05). The levels of patients without atrial fibrillation in the hyperthyroidism group were higher than those without atrial fibrillation in the coronary heart disease group(P<0.05), Patients with persistent atrial fibrillation were higher than those with paroxysmal atrial fibrillation(t/P=9.647/<0.001, 2.584/0.012, 13.133/<0.001, 3.559/<0.001). Comparison of serum TSH levels in patients with hyperthyroidismcoronary heart disease>healthy control group(F/P=472.196/<0.001, 506.342/<0.001). Pearson correlation analysis showed that PRA was positively correlated with TSH, while AT Ⅱ and ACE were negatively correlated with TSH(r=0.769,-0.792,-0.803,P<0.001); ACE was positively correlated with FT3 and FT4(r=0.718, 0.680,P<0.001); PRA, ACE, AT Ⅱ were positively correlated with LAD(r=0.795, 0.790, 0.751,P<0.001); Logistic regression analysis showed that low TSH, high FT3, high FT4, high PRA, high ACE, and high AT Ⅱ were risk factors for atrial fibrillation in patients with coronary heart disease and hyperthyroidism [OR(95%CI)=9.080(1.694 to 48.671), 10.103(1.582 to 64.519), 10.200(1.805 to 57.643), 12.730(1.947 to 83.226), 15.123(3.684 to 62.081), 9.667(1.032 to 90.557)]. Conclusion The levels of PRA, ACE, AT Ⅱ, and LAD in patients with coronary heart disease and hyperthyroidism are abnormally elevated, and are closely related to atrial fibrillation. The activity of the renin angiotensin system is associated with TSH, FT3,FT4, and LAD, and are all independent risk factors for atrial fibrillation in patients with coronary heart disease and hyperthyroidism.

Objective To observe the efficacy of elosumab combined with conventional statins and simple statin fortification in patients with acute coronary syndrome(ACS) and the effect on the expression of high mobility group protein B1(HMGB1), amyloid protein A1(SAA1), and CC chemokine 19(CCL19) in serum. Methods From January 2021 to January 2022, 92 patients with ACS admitted to the Department of Cardiology in the North of Shanghai Ninth People's Hospital were randomly divided into a control group of 46 patients and a combined group of 46 patients. The control group was treated with simple statin intensive therapy, while the combined group was treated with elosumab combined with conventional statin therapy. Compare the efficacy and adverse reaction rates of the two groups, as well as the serum levels of HMGB1, SAA1, CCL19, and blood lipids before and after treatment. Results After 6 months of treatment, the total effective rate of the combination group was higher than that of the control group(93.48% vs. 78.26%,χ2/P=4.389/0.036); after 6 months of treatment, the serum levels of HMGB1, SAA1, and CCL19 in both groups were lower than before treatment, and the combination group was lower than the control group(t/P=6.252/<0.001, 6.225/<0.001, 4.740/<0.001); after 6 months of treatment, the serum levels of total cholesterol(TC), triglycerides(TG), and low-density lipoprotein cholesterol(LDL-C) in both groups were lower than before treatment, and high-density lipoprotein cholesterol(HDL-C) was higher than before treatment, and the reduction/increase amplitude of the combination group was greater than that of the control group(t/P=10.281/<0.001, 7.619/<0.001, 4.740/<0.001, 2.801/0.040); the incidence of adverse reactions in the combination group was lower than that in the control group(χ2/P=4.246/0.039). Conclusion The efficacy of elosumab combined with conventional statins in patients with ACS is superior to that of simple statin fortification. It can effectively reduce blood lipids, alleviate inflammatory reactions, and reduce the expression levels of serum HMGB1, SAA1, and CCL19, with high safety.